VTRS vs. LEGN, SRPT, APLS, UTHR, RXDX, RDY, KRTX, JAZZ, TEVA, and ROIV
Should you be buying Viatris stock or one of its competitors? The main competitors of Viatris include Legend Biotech (LEGN), Sarepta Therapeutics (SRPT), Apellis Pharmaceuticals (APLS), United Therapeutics (UTHR), Prometheus Biosciences (RXDX), Dr. Reddy's Laboratories (RDY), Karuna Therapeutics (KRTX), Jazz Pharmaceuticals (JAZZ), Teva Pharmaceutical Industries (TEVA), and Roivant Sciences (ROIV). These companies are all part of the "pharmaceutical preparations" industry.
Viatris vs.
Viatris (NASDAQ:VTRS) and Legend Biotech (NASDAQ:LEGN) are both large-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, dividends, valuation, analyst recommendations, community ranking, media sentiment, earnings, risk and institutional ownership.
In the previous week, Legend Biotech had 7 more articles in the media than Viatris. MarketBeat recorded 11 mentions for Legend Biotech and 4 mentions for Viatris. Viatris' average media sentiment score of 0.82 beat Legend Biotech's score of 0.27 indicating that Viatris is being referred to more favorably in the media.
Viatris has a beta of 1.17, indicating that its stock price is 17% more volatile than the S&P 500. Comparatively, Legend Biotech has a beta of -0.05, indicating that its stock price is 105% less volatile than the S&P 500.
Viatris has a net margin of 12.05% compared to Legend Biotech's net margin of 0.00%. Viatris' return on equity of 19.19% beat Legend Biotech's return on equity.
Legend Biotech received 18 more outperform votes than Viatris when rated by MarketBeat users. Likewise, 57.35% of users gave Legend Biotech an outperform vote while only 41.18% of users gave Viatris an outperform vote.
Viatris has higher revenue and earnings than Legend Biotech.
74.7% of Viatris shares are owned by institutional investors. Comparatively, 38.9% of Legend Biotech shares are owned by institutional investors. 0.3% of Viatris shares are owned by insiders. Comparatively, 0.0% of Legend Biotech shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Viatris presently has a consensus target price of $12.67, suggesting a potential upside of 34.18%. Legend Biotech has a consensus target price of $77.90, suggesting a potential upside of 13.05%. Given Viatris' higher possible upside, equities analysts clearly believe Viatris is more favorable than Legend Biotech.
Summary
Viatris beats Legend Biotech on 10 of the 16 factors compared between the two stocks.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding VTRS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartMedia Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Related Companies and Tools